Vanguard Group Inc Bio Xcel Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,187,466 shares of BTAI stock, worth $2.56 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,187,466
Previous 1,201,377
1.16%
Holding current value
$2.56 Million
Previous $732,000
40.03%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding BTAI
# of Institutions
52Shares Held
8.63MCall Options Held
34.5KPut Options Held
59.4K-
Armistice Capital, LLC New York, NY4.32MShares$9.32 Million0.02% of portfolio
-
Ubs Group Ag1.28MShares$2.76 Million0.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$951,8790.0% of portfolio
-
Geode Capital Management, LLC Boston, MA312KShares$673,8440.0% of portfolio
-
Wells Fargo & Company San Francisco, CA199KShares$429,8610.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $60.5M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...